Immune-mediated liver injury induced by PD-1/PD-L1 checkpoint inhibitors is different from idiosyncratic drug-induced liver injury

被引：0
|
作者：
Wang, Yan [1 ]
Meng, Yao [1 ]
Zhang, Mengmeng [1 ]
Guo, Tiantian [1 ]
Chen, Wei [1 ]
Liu, Liwei [2 ]
Zhao, Xinyan [1 ]
机构：
[1] Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Natl Clin Res Ctr Digest Dis,Key Lab Translat Med, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Youan Hosp, Dept Liver Dis 4, Difficult & Complicated Liver Dis & Artificial Li, Beijing, Peoples R China
来源：
JOURNAL OF HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT-326
引用
收藏
页码：S121 / S121
页数：1
相关论文
共 50 条
  • [1] New advances in the study of PD-1/PD-L1 inhibitors-induced liver injury
    Yue, Meijun
    Li, Chunyu
    Li, Guohui
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 131
  • [2] Liver Injury Caused by Green Tea Extract in PD-1-/- Mice: An Impaired Immune Tolerance Model for Idiosyncratic Drug-Induced Liver Injury
    Cho, Tiffany
    Wang, Xijin
    Yeung, Karen
    Cao, Yanshan
    Uetrecht, Jack
    CHEMICAL RESEARCH IN TOXICOLOGY, 2021, 34 (03) : 849 - 856
  • [3] Expression of PD-L1 on renal tubular epithelial cells and functional role of PD-L1/PD-1 pathway in immune-mediated injury
    Wahl, PR
    Le Hir, M
    Heemann, U
    Wang, MH
    Schoop, R
    Wuthrich, RP
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 174A - 174A
  • [4] Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Skalniak, Lukasz
    Zak, Krzysztof M.
    Musielak, Bogdan
    Rudzinska-Szostak, Ewa
    Berlicki, Lukasz
    Kocik, Justyna
    Grudnik, Przemyslaw
    Sala, Dominik
    Zarganes-Tzitzikas, Tryfon
    Shaabani, Shabnam
    Doemling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (44) : 13732 - 13735
  • [5] Treatment with PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors. Immune-mediated side effects
    Grimm, M. -O.
    Oppel-Heuchel, H.
    Foller, S.
    UROLOGE, 2018, 57 (05): : 543 - 551
  • [6] Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
    Thuru, Xavier
    Magnez, Romain
    El-Bouazzati, Hassiba
    Vergoten, Gerard
    Quesnel, Bruno
    Bailly, Christian
    CANCERS, 2022, 14 (14)
  • [7] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
  • [8] Drug-Induced Liver Injury: Understanding the Different Immune-Mediated Phenotypes and Clinical Management
    Ben L. Da
    Gil Ben-Yakov
    David Kleiner
    Christopher Koh
    Current Hepatology Reports, 2018, 17 (3) : 235 - 244
  • [9] Recent Advances in Models of Immune-Mediated Drug-Induced Liver Injury
    Tasnim, Farah
    Huang, Xiaozhong
    Lee, Christopher Zhe Wei
    Ginhoux, Florent
    Yu, Hanry
    FRONTIERS IN TOXICOLOGY, 2021, 3
  • [10] Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models
    Gerussi, Alessio
    Natalini, Ambra
    Antonangeli, Fabrizio
    Mancuso, Clara
    Agostinetto, Elisa
    Barisani, Donatella
    Di Rosa, Francesca
    Andrade, Raul
    Invernizzi, Pietro
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (09)
12345